Thomas D. Schwenger
Known title: Pres. & Chief Customer OfficerCIK: 0001788226
Associated companies
Transaction History
| VEEV | ▲ Buy | Option Exercise | 2,907 | $0 | 10/1/2026 | View on chart |
| VEEV | ▼ Sell | Tax Withholding | 1,272 | $359K | 10/1/2026 | View on chart |
| VEEV | ▼ Sell | Open Market | 1,000 | $265K | 9/14/2026 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 10,000 | $1.5M | 8/27/2026 | View on chart |
| VEEV | ▼ Sell | Open Market | 10,000 | $2.8M | 8/27/2026 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 35,000 | $5.4M | 8/13/2026 | View on chart |
| VEEV | ▼ Sell | Open Market | 1,819 | $457K | 8/13/2026 | View on chart |
| VEEV | ▼ Sell | Open Market | 1,000 | $242K | 8/13/2026 | View on chart |
| VEEV | ▼ Sell | Open Market | 33,181 | $8.3M | 8/13/2026 | View on chart |
| VEEV | ▼ Sell | Open Market | 5,000 | $1.0M | 7/16/2026 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 2,907 | $0 | 7/1/2026 | View on chart |
| VEEV | ▼ Sell | Tax Withholding | 1,117 | $206K | 7/1/2026 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 2,043 | $0 | 4/1/2026 | View on chart |
| VEEV | ▼ Sell | Tax Withholding | 588 | $102K | 4/1/2026 | View on chart |
| VEEV | ▼ Sell | Open Market | 1,000 | $200K | 3/5/2026 | View on chart |
| VEEV | ▼ Sell | Open Market | 1,000 | $231K | 1/13/2026 | View on chart |
| VEEV | ▼ Sell | Tax Withholding | 631 | $141K | 1/1/2026 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 2,042 | $0 | 1/1/2026 | View on chart |
| VEEV | ▼ Sell | Gift | 980 | $0 | 10/8/2025 | View on chart |
| VEEV | ▼ Sell | Open Market | 3,350 | $1.0M | 10/2/2025 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 2,043 | $0 | 10/1/2025 | View on chart |
| VEEV | ▼ Sell | Tax Withholding | 894 | $262K | 10/1/2025 | View on chart |
| VEEV | ▼ Sell | Tax Withholding | 808 | $229K | 7/1/2025 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 2,043 | $0 | 7/1/2025 | View on chart |
| VEEV | ▼ Sell | Open Market | 1,150 | $308K | 5/29/2025 | View on chart |
| VEEV | ▼ Sell | Open Market | 802 | $177K | 4/14/2025 | View on chart |
| VEEV | ▼ Sell | Open Market | 398 | $88K | 4/14/2025 | View on chart |
| VEEV | ▼ Sell | Open Market | 380 | $80K | 4/10/2025 | View on chart |
| VEEV | ▼ Sell | Open Market | 740 | $157K | 4/10/2025 | View on chart |
| VEEV | ▼ Sell | Open Market | 610 | $130K | 4/10/2025 | View on chart |
| VEEV | ▼ Sell | Open Market | 870 | $187K | 4/10/2025 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 1,909 | $0 | 4/1/2025 | View on chart |
| VEEV | ▼ Sell | Tax Withholding | 549 | $125K | 4/1/2025 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 1,909 | $0 | 1/1/2025 | View on chart |
| VEEV | ▼ Sell | Tax Withholding | 593 | $125K | 1/1/2025 | View on chart |
| VEEV | ▼ Sell | Open Market | 1,126 | $270K | 11/8/2024 | View on chart |
| VEEV | ▼ Sell | Tax Withholding | 835 | $173K | 10/1/2024 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 1,909 | $0 | 10/1/2024 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 1,909 | $0 | 7/1/2024 | View on chart |
| VEEV | ▼ Sell | Tax Withholding | 802 | $146K | 7/1/2024 | View on chart |
| VEEV | ▼ Sell | Tax Withholding | 652 | $150K | 4/1/2024 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 2,268 | $0 | 4/1/2024 | View on chart |
| VEEV | ▼ Sell | Open Market | 1,238 | $260K | 1/22/2024 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 2,267 | $0 | 1/1/2024 | View on chart |
| VEEV | ▼ Sell | Tax Withholding | 697 | $134K | 1/1/2024 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 2,500 | $0 | 10/1/2023 | View on chart |
| VEEV | ▼ Sell | Tax Withholding | 1,094 | $223K | 10/1/2023 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 2,268 | $0 | 10/1/2023 | View on chart |
| VEEV | ▼ Sell | Tax Withholding | 993 | $202K | 10/1/2023 | View on chart |
| VEEV | ▼ Sell | Open Market | 1,238 | $272K | 9/5/2023 | View on chart |
| VEEV | ▼ Sell | Tax Withholding | 696 | $138K | 7/1/2023 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 2,268 | $0 | 7/1/2023 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 1,765 | $0 | 4/1/2023 | View on chart |
| VEEV | ▼ Sell | Tax Withholding | 508 | $93K | 4/1/2023 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 1,764 | $0 | 1/1/2023 | View on chart |
| VEEV | ▼ Sell | Tax Withholding | 558 | $90K | 1/1/2023 | View on chart |
| VEEV | ▼ Sell | Tax Withholding | 981 | $162K | 10/1/2022 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 1,765 | $0 | 10/1/2022 | View on chart |
| VEEV | ▼ Sell | Tax Withholding | 772 | $127K | 10/1/2022 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 2,500 | $0 | 10/1/2022 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 1,765 | $0 | 7/1/2022 | View on chart |
| VEEV | ▼ Sell | Tax Withholding | 508 | $104K | 7/1/2022 | View on chart |
| VEEV | ▼ Sell | Tax Withholding | 314 | $68K | 4/1/2022 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 1,090 | $0 | 4/1/2022 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 1,090 | $0 | 1/1/2022 | View on chart |
| VEEV | ▼ Sell | Tax Withholding | 340 | $87K | 1/1/2022 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 2,500 | $0 | 10/1/2021 | View on chart |
| VEEV | ▼ Sell | Tax Withholding | 1,094 | $314K | 10/1/2021 | View on chart |
| VEEV | ▼ Sell | Tax Withholding | 477 | $137K | 10/1/2021 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 1,090 | $0 | 10/1/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Veeva Gains Investor Attention Amid R&D Growth and AI Focus
Veeva Systems is drawing investor interest as analysts note strong R&D growth and a positive outlook. The company has secured a major research partner that now uses its software as the default clinical platform, and a recent IQVIA deal expands its market reach. Large institutional investors are also increasing exposure to Veeva as part of an AI software play.
Veeva Gains Investor Attention Amid R&D Growth and AI Focus. Veeva Systems is drawing investor interest as analysts note strong R&D growth and a positive outlook. The company has secured a major research partner that now uses its software as the default clinical platform, and a recent IQVIA deal expands its market reach. Large institutional investors are also increasing exposure to Veeva as part of an AI software play.